Colon Cancer News, Articles | Today's Clinical Lab

MRD testing helps clinicians track a patient's risk of cancer recurrence by detecting small traces of circulating tumor DNA (ctDNA) in a patient's bloodstream following treatment.

Labcorp Expands MRD Testing for Breast, Lung, and Colon Cancer Recurrence Risk

LabCorp

Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer

Colorectal cancer is one of the most common cancers in the Western world.

DNA Testing of Colorectal Polyps Improves Insight into Hereditary Risks

Radboud University Medical Center

European collaboration demonstrates the value of targeted tumor analysis

The new designation adds to growing evidence of the value of the Haystack MRD test for both clinical and pharmaceutical applications.

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics

Quest Diagnostics

Could this new test change how early-stage colorectal cancer is treated and improve patient outcomes?

With these rising rates, early-onset colorectal cancer has become the leading cause of cancer-related death for men under 50 and the second-leading cause for women under 50 in the United States.

What’s Behind the Enormous Increase in Early-Onset Gastrointestinal Cancers?

Oxford University Press

The incidence of early-onset colorectal cancer is increasing globally, particularly in high-income countries

Images of positive CT colonography (CTC) screening examination result in an asymptomatic 67-year-old man. Three-dimensional colon map from CTC (left image) shows the location of two sigmoid polyps that were detected (red dots). Three-dimensional endoluminal and confirmatory two-dimensional transverse CTC images show a large 1.6-cm pedunculated polyp on top row (arrow) and a 9-mm pedunculated polyp in the distal sigmoid on the bottom row (arrow). Both polyps were confirmed and resected at optical colonoscopy performed the same day (right images), avoiding the need for a second bowel preparation. The larger polyp proved to be a tubulovillous adenoma (large advanced adenoma), whereas the smaller polyp was a nonadvanced tubular adenoma. Compare this level of information of a positive CTC screening test result with a positive multitarget stool DNA test result, for which no specific information is provided.

CT Colonography Beats Stool DNA Testing for Colon Cancer Screening

Radiological Society of North America

While both screening methods were clinically effective compared to no screening, one of them led to a better reduction of colorectal cancer incidence

Illustration of people standing together in the shape of a cancer ribbon with some people standing outside of the formation to represent people who are not getting screened for lung cancer.

Rates of Breast and Colorectal Cancer Screening Nearly Four-Fold Higher than Lung Cancer Screening, Study Finds

Mass General Brigham

A new study finds that many eligible patients who receive other preventive screenings are not getting screened for lung cancer

Photo of a clinical technician wearing PPE examining a colonoscopy on a monitor in a clinic.

New Biomarker Candidates for Colon Cancer

Michael Schubert, PhD

New biomarker candidates may help determine which colon cancer patients are most likely to benefit from chemotherapy

A person holds a magnifying lens to a vector illustration of the human intestines and excretory system.

Liquid Biopsy Not Effective for Colorectal Cancer Screening

American Gastroenterological Association

A blood test will be better than nothing, but may lead to more CRC cases and deaths than established screening tests

Three women with head scarves sit in individual chairs as they receive intravenous chemotherapy.

WHO’s Estimates Highlight Growing Global Cancer Burden

World Health Organization

The estimates report the disproportionate impact on low-resource settings and the lack of core financial health services

A pair of gloved hands load a clear, colorless liquid from a vial into a syringe.

Vaccine Candidate Delays Relapse of KRAS-Mutated Cancers

University of Texas MD Anderson Cancer Center

All patients receiving the highest dose had significant T-cell responses, correlating with a significant reduction in risk of relapse

Colon Cancer